BR112018003191A2 - uso de ureidomustina no tratamento de câncer - Google Patents

uso de ureidomustina no tratamento de câncer

Info

Publication number
BR112018003191A2
BR112018003191A2 BR112018003191A BR112018003191A BR112018003191A2 BR 112018003191 A2 BR112018003191 A2 BR 112018003191A2 BR 112018003191 A BR112018003191 A BR 112018003191A BR 112018003191 A BR112018003191 A BR 112018003191A BR 112018003191 A2 BR112018003191 A2 BR 112018003191A2
Authority
BR
Brazil
Prior art keywords
ureidomustine
cancer treatment
leukemia
acute
cancer
Prior art date
Application number
BR112018003191A
Other languages
English (en)
Inventor
Moore Malcolm
Shieh Jae-Hung
Su Tsann-Long
Lee Te-Chang
Original Assignee
Academia Sinica
Memorial Sloan Kettering Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Academia Sinica, Memorial Sloan Kettering Cancer Center filed Critical Academia Sinica
Publication of BR112018003191A2 publication Critical patent/BR112018003191A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

método de utilização de ureidomustina (bo-1055), um agente de reticulação de nda solúvel em água, no tratamento de um câncer, selecionado a partir do grupo que consiste em vários tipos de leucemia humana [tais como leucemia mieloide aguda (all) e leucemia linfoblástica b aguda (b-all)], linfomas, carcinoma de células pequenas do pulmão (sclc), sarcomas e outros.
BR112018003191A 2015-08-17 2016-08-17 uso de ureidomustina no tratamento de câncer BR112018003191A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562206081P 2015-08-17 2015-08-17
PCT/US2016/047264 WO2017031156A1 (en) 2015-08-17 2016-08-17 Use of ureidomustine (bo-1055) in cancer treatment

Publications (1)

Publication Number Publication Date
BR112018003191A2 true BR112018003191A2 (pt) 2018-12-04

Family

ID=58051562

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018003191A BR112018003191A2 (pt) 2015-08-17 2016-08-17 uso de ureidomustina no tratamento de câncer

Country Status (12)

Country Link
US (2) US10548861B2 (pt)
EP (1) EP3337784A4 (pt)
JP (1) JP2018535186A (pt)
KR (1) KR20180052617A (pt)
CN (1) CN107922321A (pt)
AU (1) AU2016308116A1 (pt)
BR (1) BR112018003191A2 (pt)
CA (1) CA2994009A1 (pt)
MX (1) MX2018002047A (pt)
SG (1) SG10202001388YA (pt)
TW (1) TWI644667B (pt)
WO (1) WO2017031156A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020068615A1 (en) * 2018-09-24 2020-04-02 Albert Einstein College Of Medicine Interleukin-8 for maintenance of human acute myeloid leukemia and myelodysplastic syndrome and uses thereof
CN109609434B (zh) * 2018-11-23 2022-08-30 湖南中医药大学 生物转化合成天麻素的方法及应用
CN109765370B (zh) * 2018-12-17 2021-11-23 杭州京北生物科技有限公司 一种前列腺癌诊断试剂盒及制备方法与应用
KR102246582B1 (ko) * 2019-04-03 2021-04-30 이화여자대학교 산학협력단 올리고펩타이드를 이용한 줄기세포의 연골세포로의 분화 유도 방법

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8222297B2 (en) * 2007-01-11 2012-07-17 Academia Sinica Aniline or phenol mustards linked to DNA-affinic molecules or water-soluble aromatic rings and their use as cancer therapeutic agents
US9193687B2 (en) * 2007-01-11 2015-11-24 Academia Sinica Phenyl N-mustard linked to DNA-affinic molecules or water-soluble aryl rings, method and their use as cancer therapeutic agents

Also Published As

Publication number Publication date
WO2017031156A1 (en) 2017-02-23
MX2018002047A (es) 2018-09-18
EP3337784A1 (en) 2018-06-27
CA2994009A1 (en) 2017-02-23
SG10202001388YA (en) 2020-04-29
JP2018535186A (ja) 2018-11-29
EP3337784A4 (en) 2019-04-17
AU2016308116A1 (en) 2018-02-15
US20190008808A1 (en) 2019-01-10
US10548861B2 (en) 2020-02-04
TWI644667B (zh) 2018-12-21
CN107922321A (zh) 2018-04-17
US20200246284A1 (en) 2020-08-06
KR20180052617A (ko) 2018-05-18
TW201711679A (zh) 2017-04-01
WO2017031156A8 (en) 2018-04-26

Similar Documents

Publication Publication Date Title
CL2016001345A1 (es) Producto farmacéutico que comprende a un inhibidor de la interacción mdm2-p53 y b citarabina y uso para el tratamiento del cáncer.
BR112018067368A2 (pt) terapia de combinação com anticorpos anti-cd73
MX2019001125A (es) Inhibidores de cinasa macrociclica.
BR112015023752A2 (pt) complexos multiespecificos monovalentes e multivalentes e seus usos
BR112017020952A2 (pt) método de tratamento de câncer, composição e uso da composição
BR112018003269A2 (pt) conjugados de fármaco-anticorpo anti-dll3 e métodos de utilização
SG10201803024SA (en) System and method for token domain control
MY192888A (en) Dna alkylating agents
CL2018000786A1 (es) Nuevos derivados de pirrolo[2,3-d]pirimidina, un proceso para su preparación y composiciones farmacéuticas que los contienen.
CL2018000677A1 (es) Derivados de 8-[6-[3-(amino)propoxi]-3-piridil]1-isopropilimidazo[4,5-c]quinolin-2-ona como moduladores selectivos de la cinasa de la ataxia telangiectasia mutada (atm) para el tratamiento del cáncer
BR112018003191A2 (pt) uso de ureidomustina no tratamento de câncer
CL2015001985A1 (es) Compuestos de tiazolcarboxamidas y piridinacarboxamida, inhibidores de quinasa pim.
WO2016179558A8 (en) K-ras modulators
IL259836B (en) Dimeric macrocyclic cations, complexes containing them and their uses as contrast agents
CL2018003444A1 (es) Derivados de adenosina para uso en el tratamiento del cancer.
MX2020002885A (es) Derivados de galnac.
BR112017025711A2 (pt) ?composições, processo para preparação de siloxanos modificados por poliéter e uso das composições inovadoras?
BR112018010279A2 (pt) novos anticorpos anti-emr2 e métodos de uso
CL2018003417A1 (es) Nuevos compuestos.
BR112017022022A2 (pt) arenavírus para uso no tratamento e/ou prevenção de tumores e método para a produção de arenavírus com propriedades de regressão de tumor (aprimoradas)
MX2019015676A (es) Uso de isovaleril espiramicina i, ii y/o iii en la fabricación de medicamentos para el tratamiento y/o la prevención de tumores, y el medicamento.
BR112018075185A2 (pt) formulações análogas de hidróxi metionina adequadas para aplicações de produtos químicos especializados
MX2019015527A (es) Conjugados y composiciones de texafirina-pt (iv) para su uso para superar la resistencia del platino.
BR112018012647A2 (pt) composto, método para tratamento de um hospedeiro, e, uso de um composto.
BR112018012884A2 (pt) novos anticorpos anti-mmp16 e métodos de uso

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A ANUIDADE.

B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2633 DE 22-06-2021 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.